VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Issues related to the Orphan Drug Tax Credit (no specific bills). Issues related to comprehensive corporate tax reform (no specific bills).
| Lobbyist | Covered position, as disclosed |
|---|---|
| SCOTT BARNES | — |
| MICHAEL MATTOON | — |
| SAMANTHA VENTIMIGLIA | — |
Health Issues HCR
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 1628 - American Health Care Act of 2017, issues related to the repeal of the Affordable Care Act (ACA); H.R. 2430 - FDA Reauthorization Act of 2017, provisions related to extending user-free programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SCOTT BARNES | — |
| MICHAEL MATTOON | — |
| SAMANTHA VENTIMIGLIA | — |
Medicare/Medicaid MMM
Issues related to rare disease and orphan disease patient access in Medicaid; H.R. 3921, the HEALTHY KIDS ACT, and S. 1827, the KIDS Act, to reauthorize the State Children's Health Insurance Program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SCOTT BARNES | — |
| MICHAEL MATTOON | — |
| SAMANTHA VENTIMIGLIA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.